Artificial intelligence algorithms are being integrated into various aspects of cancer research and care, including applications in pathology and diagnostic testing. Digital and computational pathology platforms have the potential to provide more precise and novel diagnostic insights to inform treatment decision making and, ultimately, improve patient outcomes. Friends of Cancer Research (Friends) is leading a…
Welcome to Friends’ first Quarterly Patient Advocate Newsletter of 2024. 2023 Advocacy Newsletters Newsletter Feedback Form Here’s what you can read more about in this newsletter: What’s Happening at Friends?: Read about Friends’ research to ensure diagnostic tests consistently provide reliable results for patients and providers. Mark Your Calendars: Upcoming events, including public meetings hosted…
Homologous Recombination Deficiency (HRD) is a complex biomarker that can help identify patients likely to respond to certain therapies. Friends of Cancer Research’s (Friends) HRD Harmonization Project Harmonization Project is a unique research partnership to find alignment among different assays that measure HRD, to support its use as a biomarker in clinical research and care, and to serve as a foundational…
Dear Advocates, We are excited to welcome you to the fourth edition of the Friends Advocacy Newsletter. It has been a great year working with you to create and launch this resource and we want to hear your thoughts on what you have liked, what could be improved, and what you want to see more of. We…
On November 14, 2023, Friends of Cancer Research hosted our 16th Annual Meeting in Washington, D.C. Discussions at the meeting were the culmination of three working groups led by the organization over the past year, which collaboratively proposed solutions for three key challenges in oncology drug development: dose-finding in early phase trials, incorporating pragmatic elements in clinical trials, and using data from academic-led studies for regulatory decision-making.
On Wednesday, July 20, Friends of Cancer Research (Friends) hosted a meeting titled “Expediting Drug Development: Use of ctDNA as an Early Endpoint.” Welcoming everyone, Jeff Allen, President & CEO of Friends, provided updates regarding Friends’ ctDNA for Monitoring Treatment Response (ctMoniTR) project , a unique collaboration exploring whether changes in ctDNA levels can indicate clinical…
